BINDING-SITES FOR [H-3] MELATONIN IN HUMAN PLATELETS

被引:36
|
作者
VACAS, MI [1 ]
DELZAR, MDM [1 ]
MARTINUZZO, M [1 ]
CARDINALI, DP [1 ]
机构
[1] UNIV BUENOS AIRES,HOSP CLIN JOSE DE SAN MARTIN,DIV HEMATOL,BUENOS AIRES,ARGENTINA
关键词
H-3]-MELATONIN BINDING; HUMAN PLATELETS; DIURNAL CHANGES IN MELATONIN RESPONSE;
D O I
10.1111/j.1600-079X.1992.tb00055.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A number of in vitro effects of melatonin on human platelets were revealed in previous studies. In order to examine whether high affinity binding sites for [H-3]-melatonin were present in membrane preparations of human platelets, a rapid filtration procedure through Whatman GFB paper was employed. Maximal melatonin binding was attained within 3 hr at 0-degrees-C. Scatchard analysis indicated a single population of binding sites with a dissociation constant (Kd) = 4.1 +/- 0.5 nM and maximal number of binding sites (Bmax) = 24.2 +/- 1.9 fmol/mg protein (mean +/- SEM of five experiments). When various indole analogs were tested for their ability to inhibit [H-3]-melatonin binding, the following Ki (nM) were obtained: 6-chloromelatonin (11.4), 2-iodomelatonin (22.0), melatonin (24.7), 5-methoxytryptophol (49.9), N-acetylserotonin (68.9), 6-hydroxymelatonin (78.2), 5-methoxytryptamine (184). Serotonin was a potent inhibitor of [H-3]-melatonin binding with a Ki = 20.6 nM. Except for 2-methylserotonin and alpha-methylserotonin, a number of serotonin agonists and antagonists tested did not affect melatonin binding to platelet membranes. Binding experiments carried out at either 0800 or 2000 did not reveal time-dependent differences in Kd or Bmax. The results suggest that high affinity melatonin acceptors are present in human platelets.
引用
收藏
页码:60 / 65
页数:6
相关论文
共 50 条
  • [1] HUMAN-PLATELETS POSSESS MULTIPLE [H-3]IMIPRAMINE BINDING-SITES
    IENI, JR
    ZUKIN, SR
    VANPRAAG, HM
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1984, 106 (03) : 669 - 672
  • [2] PROPERTIES OF H-3 MPTP BINDING-SITES IN HUMAN-BLOOD PLATELETS
    DELZOMPO, M
    BERNARDI, F
    BONUCCELLI, U
    MAGGIO, R
    BAJOREK, M
    ARNONE, M
    CORSINI, GU
    [J]. LIFE SCIENCES, 1986, 39 (20) : 1885 - 1891
  • [3] SOLUBILIZATION AND ASSAY OF [H-3]IMIPRAMINE BINDING-SITES FROM HUMAN-PLATELETS
    DAVIS, A
    MORRIS, J
    TANG, SW
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1983, 86 (3-4) : 353 - 359
  • [4] BINDING-SITES FOR [H-3] GLUTAMATE AND [H-3] ASPARTATE IN HUMAN CEREBELLUM
    CROSS, A
    SKAN, W
    SLATER, P
    [J]. JOURNAL OF NEUROCHEMISTRY, 1986, 47 (05) : 1463 - 1468
  • [5] IDENTIFICATION OF NONSEROTONERGIC [H-3] KETANSERIN BINDING-SITES ON HUMAN PLATELETS AND THEIR ROLE IN SEROTONIN RELEASE
    LEYSEN, JE
    GOMMEREN, W
    JANSSEN, PAJ
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1991, 206 (01): : 39 - 45
  • [6] CHARACTERIZATION OF THE 2 BINDING-SITES OF [H-3] PAF-ACETHER TO HUMAN-PLATELETS
    WADE, PJ
    TUFFIN, DP
    [J]. THROMBOSIS AND HAEMOSTASIS, 1985, 54 (01) : 241 - 241
  • [7] [H-3] IMIPRAMINE BINDING-SITES ARE DECREASED IN PLATELETS OF CHRONIC PAIN PATIENTS
    MAGNI, G
    ANDREOLI, F
    ARDUINO, C
    ARSIE, D
    CECCHERELLI, F
    AMBROSIO, F
    EANDI, M
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 1987, 75 (01) : 108 - 110
  • [8] [H-3] IMIPRAMINE BINDING-SITES ARE DECREASED IN PLATELETS OF CHRONIC PAIN PATIENTS
    MAGNI, G
    ANDREOLI, F
    ARDUINO, C
    ARSIE, D
    CECCHERELLI, F
    AMBROSIO, F
    EANDI, M
    [J]. CLINICAL NEUROPHARMACOLOGY, 1987, 10 (02) : 175 - 177
  • [9] CHARACTERIZATION OF BINDING-SITES FOR H-3 SPIROPERIDOL IN HUMAN RETINA
    MCGONIGLE, P
    WAX, MB
    MOLINOFF, PB
    [J]. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1988, 29 (05) : 687 - 694
  • [10] NONSEROTONERGIC H-3 KETANSERIN BINDING-SITES IN HUMAN PLATELETS - CHARACTERISTICS AND INTERACTION WITH CALCIUM-ANTAGONISTS
    OLIVA, D
    POCCHIARI, F
    ALLIEVI, L
    ROVATI, GE
    NICOSIA, S
    [J]. PHARMACOLOGICAL RESEARCH, 1992, 26 (02) : 187 - 199